The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.
Frese, Kristopher K
Schenk, Maximilian W
Hodgkinson, Cassandra L
Simpson, Kathryn L
Miller, Crispin J
Blackhall, Fiona H
AffiliationClinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute
MetadataShow full item record
AbstractIntroduced in 1987, platinum-based chemotherapy remains standard of care for small cell lung cancer, a most aggressive, recalcitrant tumor. Prominent barriers to progress are paucity of tumor tissue to identify drug targets and patient relevant models to interrogate novel therapies. Following our development of circulating tumour cell patient-derived explants (CDX) as models that faithfully mirror patient disease, here we exploit CDX to examine new therapeutic options for small cell lung cancer.
CitationThe combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. 2018, Clin Cancer Res
JournalClinical Cancer Research